{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:40:34Z","timestamp":1788244834077,"version":"build-2803163510"},"reference-count":13,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2007,6,20]],"date-time":"2007-06-20T00:00:00Z","timestamp":1182297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2007,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The purpose of this study was to assess the relationship between progression\u2010free survival (PFS) in patients treated with DFMO + PCV (procarbazine, CCNU, vincristine) chemotherapy for malignant gliomas with tumor cell ornithine decarboxylase (ODC) activity. Formalin\u2010fixed slides were obtained for study patients with anaplastic gliomas (AGs) and glioblastoma treated on protocol DM92\u2010035. ODC levels were measured using an antibody to ODC coupled to Alexa 647 dye (Ab\u2010ODC\u2010Alexa 647). Ab\u2010ODC\u2010Alexa 647 intensity in transgenic murine hearts of differing ODC activity was used to calculate ODC activity in tumor cell nucleoplasm. In total, tumor specimens for 31 of 114 (27%) patients treated on the AG strata and 10 patients from the GBM strata were obtained. We found that tumor ODC level heterogeneity increased with increasing tumor malignancy. In a Cox proportional hazards model, PFS was found to be inversely related to median tumor ODC activity, with an unadjusted hazard ratio for median ODC group (&gt;3.3 <jats:italic>vs.<\/jats:italic> \u22643.3 nmol\/30 min\/\u03bcg protein) of 5.8 (<jats:italic>p<\/jats:italic> &lt; 0.0001); a median PFS of 522 weeks for patients with AGs with median ODC activity \u2264 3.3 and 31 weeks for the 8 AG and 10 glioblastoma patients with ODC activity &gt; 3.3 nmol\/30 min\/\u03bcg protein. Of AG tumors in which ODC activity was evaluated, 26% had ODC levels &gt; 3.3 nmol\/30 min\/\u03bcg protein. This study shows that Ab\u2010ODC\u2010Alexa 647 fluorescence intensity can be used as a surrogate marker of ODC biochemical activity in AGs and can predict PFS to DFMO\u2010based chemotherapy. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.22914","type":"journal-article","created":{"date-parts":[[2007,6,20]],"date-time":"2007-06-20T14:47:31Z","timestamp":1182350851000},"page":"2279-2283","source":"Crossref","is-referenced-by-count":15,"title":["Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression\u2010free survival in patients treated with DFMO\u2013PCV chemotherapy"],"prefix":"10.1002","volume":"121","author":[{"given":"Victor A.","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob L.","family":"Jochec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Shantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D.","family":"Aldape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,20]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"1661","article-title":"Selective inhibition of cell proliferation and BCR\u2010ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR\u2010ABL protein by a tyrosine kinase inhibitor (CGP\u201057148)","volume":"4","author":"Beran M","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000055190"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050736"},{"key":"e_1_2_6_6_2","first-page":"459","article-title":"Phase I\u2010II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors","volume":"71","author":"Levin VA","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.18.1432"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-198906000-00003"},{"key":"e_1_2_6_9_2","first-page":"3878","article-title":"Phase III randomized study of postradiotherapy chemotherapy with alpha\u2010difluoromethylornithine\u2010procarbazine, N\u2010(2\u2010chloroethyl)\u2010N\u2032\u2010cyclohexyl\u2010N\u2010nitrosurea, vincristine (DFMO\u2013PCV) versus PCV for glioblastoma multiforme","volume":"6","author":"Levin VA","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_10_2","first-page":"981","article-title":"Phase III randomized study of postradiotherapy chemotherapy with combination alpha\u2010difluoromethylornithine\u2010PCV versus PCV for anaplastic gliomas","volume":"9","author":"Levin VA","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1369\/jhc.4A6358.2004"},{"key":"e_1_2_6_12_2","first-page":"2748","article-title":"Ornithine decarboxylase induction in transformation by H\u2010Ras and RhoA","volume":"58","author":"Shantz LM","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_6_13_2","first-page":"117","article-title":"6\u2010Aminonicotinamide sensitizes human tumor cell lines to cisplatin","volume":"4","author":"Budihardjo II","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj3580025"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.22914","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.22914","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.22914","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.22914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T11:08:02Z","timestamp":1693220882000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.22914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,20]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,11,15]]}},"alternative-id":["10.1002\/ijc.22914"],"URL":"https:\/\/doi.org\/10.1002\/ijc.22914","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,20]]}}}